Gestalt Diagnostics, Spokane, Wash., and Deep Bio, Seoul, South Korea, announced their strategic relationship for the development of an integrated workflow for pathologists to use artificial intelligence algorithms directly within Gestalt’s PathFlow platform. Deep Bio’s algorithm analyzes whole slide images (WSIs) of H&E-stained prostate core needle biopsy tissue specimens to detect and classify prostate cancer. Using the PathFlow platform with Deep Bio’s AI analysis provides pathologists with an enhanced support tool for diagnosing prostate cancer.
“Optimizing the pathology workflow with an interoperable solution that combines the value of Gestalt’s full digital pathology platform and Deep Bio’s DeepDx AI algorithms enables a high throughput diagnostic process,” says Gestalt COO and Chief Strategy Officer Lisa-Jean Clifford. “Providing pathologists with instant access to AI algorithms directly within their workflow presents them with key data in real-time, shortening the time to diagnosis for cancer patients. We are excited to be collaborating with Deep Bio to provide pathology labs, and pathologists, with this superior solution.”
“Deep Bio’s relationship with Gestalt Diagnostics brings us one step closer to our vision of supporting pathologists and oncologists with timely and accurate diagnosis and prognosis, for better treatment decision-making,” says Deep Bio’s Founder and CEO Sun Woo Kim. “We believe our AI-powered DeepDx is a powerful addition to the seamless and integrated clinical workflow afforded by PathFlow.”
Featured image: Prostate cancer of a human, highly detailed segment of panorama. Photo: ID 66313345 © Viachaslau Bondarau | Dreamstime.com
